Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
It is widely recognized that there is a gap between basic biomedical research and medical applications. This gap derives from
the need of a process of technology transfer to private companies that will eventually exploit those applications. Such process
is complex and involves a number of players, i.e., scientists, technology transfer officers, legal advisors and business people so
it can take from months to years. Also, there is an increasing concern about the fact that many scientists concentrate most of
their efforts in publishing papers in order to be more competitive, so that in the next grant application their research group
will receive a new grant. All these facts bring the obvious result, i.e., biomedical research is normally not translated into the
practical applications that should bring the expected benefit for patients, despite the large investment that many countries
make in basic research. A clear example of this problem is the small number of new drugs that have been developed in the
last decade, despite the promise that, after sequencing the first draft of the human genome, a wave of new therapies would be
developed. Similarly, more than a decade after the first draft of the human genome was obtained thousands of human genetic
diseases still do not have a known molecular basis. In this talk the author will present my personal experience in translating
basic knowledge in genetics and genomics into medical applications through entrepreneurship in science, mainly in two fields:
Medical Genetics and Drug Discovery. Also, he will present the Spanish Association of Entrepreneurs in Science and the need
to create the European Association of Entrepreneurs in Science.
Manuel P?rez Alonso has a degree in Biology and PhD in Molecular Genetics. He is Genetics Professor at the University of Valencia. He participated in five
international genome sequencing consortia and (as PI) in a number of basic research projects. He is promoter and founding partner in four biomedical companies:
Valentia BioPharma, The Institute of Genomic Medicine, GenAGen and Genera Biotech all of them located at the University of Valencia Science Park. His research
is now focused in the development of genomics tools for genetic testing. He also contributes to biopharmaceutical research through the study of the pathways
leading to rare genetic disease. He is President of the Valencia BioRegion (BIOVAL) and President of the Spanish Association of Entrepreneurs in Science.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals